News headlines about Tocagen (NASDAQ:TOCA) have trended somewhat positive on Sunday, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tocagen earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.3150945748372 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

TOCA has been the topic of several research analyst reports. Stifel Nicolaus reissued a “buy” rating and set a $24.00 target price on shares of Tocagen in a research note on Tuesday, July 25th. Zacks Investment Research cut Tocagen from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th.

Tocagen (NASDAQ:TOCA) remained flat at $$10.00 on Friday. 108,013 shares of the company traded hands, compared to its average volume of 309,430. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.03 and a current ratio of 6.03. Tocagen has a twelve month low of $8.60 and a twelve month high of $17.95.

Tocagen (NASDAQ:TOCA) last posted its earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.02). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. sell-side analysts anticipate that Tocagen will post -2.88 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Tocagen (TOCA) Share Price” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at

About Tocagen

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Insider Buying and Selling by Quarter for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.